Clinical analysis reveals progressive discontinuation of glucagon-like peptide-1 receptor agonists in diabetes and obesity, highlighting adherence challenges.
Type 2 diabetes (T2D) is a crucial disease, and glucagon-like peptide 1 receptor agonists (GLP-1RA) have become prevalent as effective oral hypoglycemic agents (OHA). GLP-1RA has clinical effects such as improving glucose variability, reducing weight, and decreasing the risk of cardiovascular disease (CVD). However, recent problems include discontinuation, dropout, and incomplete adherence to GLP-1RA. The discontinuation rates of GLP-1RA were 26.2%, 30.8%, and 36.5% at 3, 6, and 12 months, respectively, and increased to 50.3% for obese patients without T2D. Discontinuation was significantly higher for patients with heart failure (odds ratio 1.09) and CVD (1.08), but not for those with CKD (1.03).
No takes yet. Share an insight, caveat, or question.
Hiroshi Bando (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: